Mehdi Razavi

Dr. Mehdi Razavi is an Associate Professor of Medicine-Cardiology at Baylor College of Medicine and Director of the Electrophysiology Clinical Research & Innovations program at the Texas Heart Institute. He holds clinical appointments at multiple institutions including CHI St. Luke's Health and serves as an Editorial Consultant for the Texas Heart Institute Journal. With board certifications in Internal Medicine, Cardiovascular Disease, and Clinical Cardiac Electrophysiology, Dr. Razavi bridges clinical practice with cutting-edge research.

• Education: MD from Medical College of Pennsylvania (1995), Residency and Fellowships at Mayo Graduate School of Medicine (1998-2002)
• Academic Affiliations: Baylor College of Medicine, Texas Heart Institute, Rice University, University of Houston, Texas A&M University, UCLA

His research focuses on cardiac electrophysiology, atrial fibrillation, and biomedical device innovation. He has pioneered technologies like battery-less pacemakers, carbon nanotube fibers, and photoacoustic lesion mapping, with 18 patents to his name. Collaborations with engineering teams at Rice and Texas A&M drive his work in clinical cardiac electrophysiology and device development.

Recent publications highlight his expertise in machine learning for arrhythmia detection, graphene-based nanomaterials for cardiac repair, and ethanol ablation techniques. Notably, his 2024 JMIR Mental Health study on stress monitoring and 2024 Sci Rep work on photoacoustic cardiac imaging demonstrate interdisciplinary innovation.

• Scientific Awards:
  • Texas Super Doctors (2024, 2023, 2022, 2021)
  • Robert J. Hall Outstanding Cardiology Faculty Teaching Award (2006, 2013)
  • Texas Heart Institute EP Teaching Attending of the Year (2019)
  • Pfizer Award for Electrophysiology Training (2002)

Dr. Razavi leads the TMC Biodesign Program Mentorship and maintains active clinical trial participation. His work spans biomaterials, cardiac device development, and machine learning diagnostics, with a strong emphasis on translational research from bench to bedside. As a founder of multiple medical device startups, he drives commercialization of cardiovascular innovations.